Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 4.

Blaes, J; Weiler, M; Sahm, F; Hentschel, B; Osswald, M; Czabanka, M; Thomé, C M; Schliesser, M G; Pusch, S; Luger, S; Winkler, F; Radbruch, A; Jugold, M; Simon, M; Steinbach, J P; Schackert, G; Tatagiba, M; Westphal, M; Tonn, J C; Gramatzki, D; Pietsch, T; Hartmann, C; Glimm, H; Vajkoczy, P; von Deimling, A; Platten, M; Weller, M; Wick, W (2014). NDRG1 prognosticates the natural course of disease in WHO grade II glioma. Journal of Neuro-Oncology, 117(1):25-32.

Weiler, M; Blaes, J; Pusch, S; Sahm, F; Czabanka, M; Luger, S; Bunse, L; Solecki, G; Eichwald, V; Jugold, M; Hodecker, S; Osswald, M; Meisner, C; Hielscher, T; Rübmann, P; Pfenning, P N; Ronellenfitsch, M; Kempf, T; Schnölzer, M; Abdollahi, A; Lang, F; Bendszus, M; von Deimling, A; Winkler, F; Weller, M; Vajkoczy, P; Platten, M; Wick, W (2014). mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 111(1):409-414.

Weiler, M; Pfenning, P N; Thiepold, A L; Blaes, J; Jestaedt, L; Gronych, J; Dittmann, L M; Berger, B; Jugold, M; Kosch, M; Combs, S E; von Deimling, A; Weller, M; Bendszus, M; Platten, M; Wick, W (2013). Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment. Oncogene, 32(9):1099-1109.

Opitz, C A; Litzenburger, U M; Sahm, F; Ott, M; Tritschler, I; Trump, S; Schumacher, T; Jestaedt, L; Schrenk, D; Weller, M; Jugold, M; Guillemin, G J; Miller, C L; Lutz, C; Radlwimmer, B; Lehmann, I; von Deimling, A; Wick, W; Platten, M (2011). An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 478(7368):197-203.

This list was generated on Mon Sep 25 03:06:17 2017 CEST.